Stockscreener 앱 받기
82.63
1.42%
-1.19
시장 영업 전:
83.01
0.38
+0.46%
전일 마감가:
$83.82
열려 있는:
$88
하루 거래량:
10.52M
Relative Volume:
2.02
시가총액:
$47.58B
수익:
$6.30B
순이익/손실:
$1.07B
주가수익비율:
44.89
EPS:
1.8406
순현금흐름:
$1.09B
1주 성능:
-3.62%
1개월 성능:
-7.84%
6개월 성능:
-1.23%
1년 성능:
+9.01%
1일 변동 폭
$82.53
$89.08
1주일 범위
$82.53
$89.08
52주 변동 폭
$72.30
$96.29
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences stock trades steady as TAVR growth supports margins - Ad-hoc-news.de
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium - Yahoo Finance
Edwards Lifesciences Corp (EW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edwards Lifesciences Corp (EW) Institutional Confidence - TradingKey
EW|Edwards Lifesciences Corp|Price:82.630|Chg%:-1.185 - TradingKey
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion - MedTech Dive
Why is Edwards Lifesciences stock rallying today? By Investing.com - Investing.com South Africa
Why is Edwards Lifesciences stock rallying today? - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Receives Upgrade from Leerink with New Price Target - GuruFocus
Edwards Lifesciences Reports Strong Q2 2026 Results With 13.6% Sales Growth, Raises Full-Year Guidance - Minichart
Piper Sandler raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Edwards lifts FY26 growth outlook following steady Q2 performance - Yahoo Finance
Edwards Lifesciences Corporatio (EW) Stock Forecasts - Yahoo Finance
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Life - Benzinga
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises - Yahoo Finance
EDWARDS LIFESCIENCES CORP : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $101 FROM $87 - Bitget
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating - marketscreener.com
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum - Investing.com
Edwards Lifesciences stock holds focus on margin and growth - AD HOC NEWS
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum By Investing.com - Investing.com Canada
Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 - marketscreener.com
EW|Edwards Lifesciences Corp|Price:83.800|Chg%:-0.570 - TradingKey
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo! Finance Canada
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements - GuruFocus
Edwards Lifesciences Announces Q2 2026 Financial Results Highlighting Market Leadership - Kalkine Media
Edwards Lifesciences (EW) Reports Strong Q2 2026 Sales Growth - GuruFocus
Edwards Lifesciences Q2 Earnings Call Highlights - Yahoo Finance
Edwards Lifesciences earnings up next: TAVR momentum in focus - Investing.com UK
Earnings call transcript: Edwards Lifesciences tops Q2 2026 estimates, lifts sales outlook - Investing.com
Edwards Lifesciences (EW) Reports Strong Q2 Earnings, Raises Rev - GuruFocus
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Edwards Lifesciences Jumps After Strong Q2 Growth and Higher 2026 Sales Outlook - Moomoo
Edwards Lifesciences jumps after strong Q2 growth and higher 2026 sales outlook - Quiver Quantitative
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth - WSJ
Is Edwards Lifesciences (EW) Undervalued After Q2 Earnings Beat? - GuruFocus
Edwards Lifesciences Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set - marketscreener.com
Edwards Lifesciences soars 6% on strong Q2 results, raised sales guidance - Investing.com
Edwards Lifesciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
EDWARDS LIFESCIENCES ($EW) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Edwards Lifesciences earnings up next: TAVR momentum in focus By Investing.com - Investing.com South Africa
US28176EAD0 Bond Profile — Key Metrics - TradingView
Edwards Lifesciences stock trades steady as transcatheter heart valve revenue grows - AD HOC NEWS
Lobbying Update: $280,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Quiver Quantitative
Edwards Lifesciences stock advances on earnings and guidance - Ad-hoc-news.de
TD Cowen reiterates Edwards Lifesciences stock Buy rating on TAVR growth - Investing.com
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
2.27%
자본화:
|
볼륨(24시간):